Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-0310 in healthy volunteers
NCT06782477Phase 1Active, not recruiting
- Sponsor
- Astria Therapeutics
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of STAR0310 (5 arms), sponsored by Astria Therapeutics. Primary endpoint: Treatment-emergent Adverse Events at 252 days. Started Jan 2025; status: active, not recruiting.
02
Drugs
STAR0310
Beyond the preview
Go deeper on NCT06782477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06782477.